Communicators
are winners!
News
03.06.2009
Salugen (SYMBOL: SQZ.F) Announces Publication of Study Showing HAVEOS Can Reduce Cravings for Alcoholics Suspected of Crime
Salugen (SYMBOL: SQZ.F) Announces Publication of Study Showing HAVEOS Can Reduce Cravings for Alcoholics Suspected of Crime
Publication of Alternative Sentencing Pilot Study Conducted in Las Vegas Demonstrates Salugen Technology Significantly Reduces Cravings of Persons Facing Criminal Charges
ZURICH, SWITZERLAND and SAN DIEGO, CA USA – June 3, 2009 – Salugen® (SYMBOL: SQZ.F), a publicly-traded international life sciences company, announces today the publication of a 76-patient alternative sentencing pilot study demonstrating significant improvement in both cravings and relapse scores of alcoholics.*
Published in the peer-reviewed medical journal Advances in Therapy, this study evaluated the effects of HAVEOS (Preveras) on outcomes in a one year prospective comprehensive outpatient clinical program. HAVEOS (preveras)™ was administered for the treatment of substance use disorder. Seventy-six patients (45 males and 31 females; mean age, 33 years old [standard deviation, 7.0]) who had been given a diagnosis of serious substance use disorder were recruited. After exclusion of 15 patients who dropped out before the end of the study, self-reported craving decreased from program entrance to 12 weeks for 61 compliant patients (mean, 2.85 on a scale of 0 to 5; 95% confidence interval [CI], 2.65, 3.05); this improvement was significant (p<.001). During the study, the alcoholic dropout rate was only 7% (4 of 57).
This study demonstrates that the Salugen Preveras technology may be an effective treatment to help reduce cravings associated with the burden of alcoholism and drug addiction on the judicial system. Substance use disorder (SUD) is considered a global epidemic. A study prepared by The Lewin Group for the National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism estimated the total economic cost of alcohol and drug abuse at $245.7 billion.
Salugen is expanding the commercial availability of its HAVEOS (Preveras) product and the associated Salugen System starting this summer. This published study adds to the existing published scientific data supporting the Salugen technology. For more information or download published studies on Salugen’s technology, contact Salugen or visit. http://www.salugen.com.
About Salugen AG
Salugen™ is a life sciences company offering nutritional ingredients and gene testing to help reduce excessive cravings involved in smoking, weight problems, and alcohol and drug abuse. Salugen has a patent-protected, clinically proven nutritional formulation to reduce stress and cravings, as well as patent-protected gene tests to help identify these persons and customize their treatment. Simply, Salugen’s goal is to reduce or eliminate the illness, costs, and deaths associated with these preventable disorders. For additional information about the company, please visit http://www.salugen.com.
Investor Relations Information Contact:
Petjo Noack, MA and Louis Philippe Antunes
Sherbrooke Equity Inc.
Seefeldstrasse 45
8032 Zürich
Tel.: 41 (0) 43 443 70 70
Fax.: 41 (0) 43 443 70 77
Web: www.sherbrookequity.com
Email: info@sherbrookeequity.com
Company Information Contact: Salugen AG, 877-258-4360, info@salugen.com, http://www.salugen.com .
* These statements have not been evaluated by the U.S. Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease
Forward Looking Statements
Certain statements in this press release are forward-looking. These forward-looking statements include references to the use of our laboratory tests and nutritional products. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that physicians may not use the testing or products correctly; risks and uncertainties relating to the performance of our products; the growth in revenues; the size, timing and success or failure of any clinical trials; whether larger confirmatory clinical studies will confirm the results of initial studies; our ability to establish reliable, high-volume operations at commercially reasonable costs; expected reliance on physicians selling our products for a majority of our revenues; the annual renewal of certain customer agreements; actual market acceptance of our products and adoption of our technological approach and products; our estimate of the size of our markets; our estimates of the levels of demand for our products; the impact of competition; whether payers will authorize reimbursement for our products and services and the amount of such reimbursement that may be allowed; whether the FDA or any other agency will decide to further regulate our products or services; whether actions by the FDA, FTC or any other state regulatory body will restrict our ability to commercialize our products; whether we will encounter problems or delays in automating our processes; the ultimate validity and enforceability of our patent applications and patents; the possible infringement of the intellectual property of others; whether licenses to third party technology will be available; whether we are able to build brand loyalty and expand revenues; and whether we will be able to raise sufficient capital in the future, if required. We do not undertake, and specifically disclaim any obligation, to revise any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements.
NEWSLETTER REGISTRIERUNG:
Aktuelle Pressemeldungen dieses Unternehmens direkt in Ihr Postfach:
http://www.irw-press.com/alert_subscription.php?lang=en&isin=CH0027529517
Mitteilung übermittelt durch IRW-Press.com. Für den Inhalt ist der Aussender
verantwortlich.
Kostenloser Abdruck mit Quellenangabe erlaubt.
Publication of Alternative Sentencing Pilot Study Conducted in Las Vegas Demonstrates Salugen Technology Significantly Reduces Cravings of Persons Facing Criminal Charges
ZURICH, SWITZERLAND and SAN DIEGO, CA USA – June 3, 2009 – Salugen® (SYMBOL: SQZ.F), a publicly-traded international life sciences company, announces today the publication of a 76-patient alternative sentencing pilot study demonstrating significant improvement in both cravings and relapse scores of alcoholics.*
Published in the peer-reviewed medical journal Advances in Therapy, this study evaluated the effects of HAVEOS (Preveras) on outcomes in a one year prospective comprehensive outpatient clinical program. HAVEOS (preveras)™ was administered for the treatment of substance use disorder. Seventy-six patients (45 males and 31 females; mean age, 33 years old [standard deviation, 7.0]) who had been given a diagnosis of serious substance use disorder were recruited. After exclusion of 15 patients who dropped out before the end of the study, self-reported craving decreased from program entrance to 12 weeks for 61 compliant patients (mean, 2.85 on a scale of 0 to 5; 95% confidence interval [CI], 2.65, 3.05); this improvement was significant (p<.001). During the study, the alcoholic dropout rate was only 7% (4 of 57).
This study demonstrates that the Salugen Preveras technology may be an effective treatment to help reduce cravings associated with the burden of alcoholism and drug addiction on the judicial system. Substance use disorder (SUD) is considered a global epidemic. A study prepared by The Lewin Group for the National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism estimated the total economic cost of alcohol and drug abuse at $245.7 billion.
Salugen is expanding the commercial availability of its HAVEOS (Preveras) product and the associated Salugen System starting this summer. This published study adds to the existing published scientific data supporting the Salugen technology. For more information or download published studies on Salugen’s technology, contact Salugen or visit. http://www.salugen.com.
About Salugen AG
Salugen™ is a life sciences company offering nutritional ingredients and gene testing to help reduce excessive cravings involved in smoking, weight problems, and alcohol and drug abuse. Salugen has a patent-protected, clinically proven nutritional formulation to reduce stress and cravings, as well as patent-protected gene tests to help identify these persons and customize their treatment. Simply, Salugen’s goal is to reduce or eliminate the illness, costs, and deaths associated with these preventable disorders. For additional information about the company, please visit http://www.salugen.com.
Investor Relations Information Contact:
Petjo Noack, MA and Louis Philippe Antunes
Sherbrooke Equity Inc.
Seefeldstrasse 45
8032 Zürich
Tel.: 41 (0) 43 443 70 70
Fax.: 41 (0) 43 443 70 77
Web: www.sherbrookequity.com
Email: info@sherbrookeequity.com
Company Information Contact: Salugen AG, 877-258-4360, info@salugen.com, http://www.salugen.com .
* These statements have not been evaluated by the U.S. Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease
Forward Looking Statements
Certain statements in this press release are forward-looking. These forward-looking statements include references to the use of our laboratory tests and nutritional products. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that physicians may not use the testing or products correctly; risks and uncertainties relating to the performance of our products; the growth in revenues; the size, timing and success or failure of any clinical trials; whether larger confirmatory clinical studies will confirm the results of initial studies; our ability to establish reliable, high-volume operations at commercially reasonable costs; expected reliance on physicians selling our products for a majority of our revenues; the annual renewal of certain customer agreements; actual market acceptance of our products and adoption of our technological approach and products; our estimate of the size of our markets; our estimates of the levels of demand for our products; the impact of competition; whether payers will authorize reimbursement for our products and services and the amount of such reimbursement that may be allowed; whether the FDA or any other agency will decide to further regulate our products or services; whether actions by the FDA, FTC or any other state regulatory body will restrict our ability to commercialize our products; whether we will encounter problems or delays in automating our processes; the ultimate validity and enforceability of our patent applications and patents; the possible infringement of the intellectual property of others; whether licenses to third party technology will be available; whether we are able to build brand loyalty and expand revenues; and whether we will be able to raise sufficient capital in the future, if required. We do not undertake, and specifically disclaim any obligation, to revise any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements.
NEWSLETTER REGISTRIERUNG:
Aktuelle Pressemeldungen dieses Unternehmens direkt in Ihr Postfach:
http://www.irw-press.com/alert_subscription.php?lang=en&isin=CH0027529517
Mitteilung übermittelt durch IRW-Press.com. Für den Inhalt ist der Aussender
verantwortlich.
Kostenloser Abdruck mit Quellenangabe erlaubt.